BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3229 related articles for article (PubMed ID: 28539557)

  • 21. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
    Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA
    Front Immunol; 2018; 9():2740. PubMed ID: 30559740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors.
    Jin C; Yu D; Essand M
    Immunotherapy; 2016 Dec; 8(12):1355-1361. PubMed ID: 28000533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
    Gowrishankar K; Birtwistle L; Micklethwaite K
    Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
    Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
    Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric Antigen Receptor T Cell Therapy in Hematology.
    Ataca P; Arslan Ö
    Turk J Haematol; 2015 Dec; 32(4):285-94. PubMed ID: 26377367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
    Houot R; Schultz LM; Marabelle A; Kohrt H
    Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
    Miliotou AN; Papadopoulou LC
    Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.
    Huang Y; Li D; Qin DY; Gou HF; Wei W; Wang YS; Wei YQ; Wang W
    Gene Ther; 2018 Jun; 25(3):192-197. PubMed ID: 28820501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adoptive T-Cell Therapy for Solid Malignancies.
    Jafferji MS; Yang JC
    Surg Oncol Clin N Am; 2019 Jul; 28(3):465-479. PubMed ID: 31079800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Augmenting engineered T-cell strategies in solid cancers through epigenetic priming.
    Nielsen AY; Ormhøj M; Traynor S; Gjerstorff MF
    Cancer Immunol Immunother; 2020 Nov; 69(11):2169-2178. PubMed ID: 32648166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors.
    Dammeijer F; Lau SP; van Eijck CHJ; van der Burg SH; Aerts JGJV
    Cytokine Growth Factor Rev; 2017 Aug; 36():5-15. PubMed ID: 28693973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
    Siegler EL; Wang P
    Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating CAR-T Cell Therapy in a Hypoxic 3D Tumor Model.
    Ando Y; Siegler EL; Ta HP; Cinay GE; Zhou H; Gorrell KA; Au H; Jarvis BM; Wang P; Shen K
    Adv Healthc Mater; 2019 Mar; 8(5):e1900001. PubMed ID: 30734529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens.
    Xu J; Tian K; Zhang H; Li L; Liu H; Liu J; Zhang Q; Zheng J
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1099-1106. PubMed ID: 29048935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric Antigen Receptors for the Tumour Microenvironment.
    Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
    Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.
    Zhang T; Tai Z; Miao F; Zhang X; Li J; Zhu Q; Wei H; Chen Z
    J Control Release; 2024 Apr; 368():372-396. PubMed ID: 38408567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
    Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
    Front Immunol; 2020; 11():784. PubMed ID: 32457745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving homing in T cell therapy.
    Vignali D; Kallikourdis M
    Cytokine Growth Factor Rev; 2017 Aug; 36():107-116. PubMed ID: 28690108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells.
    Abken H
    Hum Gene Ther; 2017 Nov; 28(11):1047-1060. PubMed ID: 28810803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adoptive T-Cell Therapy for Solid Tumors.
    Yeku O; Li X; Brentjens RJ
    Am Soc Clin Oncol Educ Book; 2017; 37():193-204. PubMed ID: 28561728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 162.